6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (22).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“If the patient is meeting A1C target, consider one of three strategies (39):”
BackgroundOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“but to be used as a broad construct to guide clinical decision making (40) in both type 1 and type 2 diabetes.”
BackgroundAdler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · cited 7×
“However, outcome studies have clearly shown A1C to be the primary predictor of complications, and landmark trials of glycemic control such as the DCCT and UKPDS relied overwhelmingly on preprandial SMBG. Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens tar…”
BackgroundInfluentialHyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062 · cited 2×
“For further information on the management of diabetic ketoacidosis and the nonketotic hyperglycemic hyperosmolar state, please refer to the ADA consensus report “Hyperglycemic Crises in Adult Patients With Diabetes” (60).”
BackgroundTranslating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · cited 2×
“with type 2 diabetes, a history of level 3 hypoglycemia was associated with greater risk of dementia (48).”
BackgroundSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 1×
“of the VADT cohort (33) showed a reduction in the risk of cardiovascular events (52.”
Background(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.193 · Cited by 653
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Long-term effect of diabetes and its treatment on cognitive function
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa066397 · Cited by 646
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645 · cited 1×
“For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (56,57).”
BackgroundFollow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Increased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539 · cited 1×
“mia and 5-year mortality has also been reported in clinical practice (52) Young children with type 1 diabetes and the elderly, including those with”
BackgroundThe fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477 · cited 3×
“and A1C within an individual correlates over time (5).”
BackgroundMethodInfluentialAssociation, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Self-citationAssociation between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411 · cited 1×
“counterregulation and hypoglycemia awareness in many patients (59).”
BackgroundPotential overtreatment of diabetes mellitus in older adults with tight glycemic control
Lipska, K. J., Ross, J. S., Miao, Y., Shah, N. D., Lee, S. J., & Steinman, M. A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7345 · Cited by 408 · cited 1×
“of hypoglycemia, advanced atherosclerosis, or advanced age/frailty may benefit from less aggressive targets (36,37).”
BackgroundWheeler, E., Leong, A., Liu, C.-T., Hivert, M.-F., Strawbridge, R. J., Podmore, C., Li, M., Yao, J., Sim, X., Hong, J., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002383 · Cited by 408
Albers, J. W., Herman, W. H., Pop-Busui, R., Feldman, E. L., Martin, C. L., Cleary, P. A., Waberski, B. H., Lachin, J. M., & for the DCCT/EDIC Research Group (2010) · Diabetes Care · doi:10.2337/dc09-1941 · Cited by 401
Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Little, R. R., Rohlfing, C. L., & Sacks, D. B. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148841 · Cited by 365
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · cited 1×
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (42).”
BackgroundPoor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes
Punthakee, Z., Miller, M. E., Launer, L. J., Williamson, J. D., Lazar, R. M., Cukierman-Yaffee, T., Seaquist, E. R., Ismail-Beigi, F., Sullivan, M. D., Lovato, L. C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1855 · Cited by 337
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) · Diabetes · doi:10.2337/db14-0930 · Cited by 333
Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels
Bergenstal, R. M., Gal, R. L., Connor, C. G., Gubitosi-Klug, R., Kruger, D., Olson, B. A., Willi, S. M., Aleppo, G., Weinstock, R. S., Wood, J., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2596 · Cited by 306
Lee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226 · cited 1×
“As discussed further below, severe hypoglycemia is a potent marker of high absolute risk of cardiovascular events and mortality (38).”
BackgroundVijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185 · cited 1×
“of hypoglycemia, advanced atherosclerosis, or advanced age/frailty may benefit from less aggressive targets (36,37).”
BackgroundDuckworth, W. C., Abraira, C., Moritz, T. E., Davis, S. N., Emanuele, N., Goldman, S., Hayward, R., Huang, G. D., Marks, J. B., Reaven, P. D., et al. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.10.003 · Cited by 152
Protein in optimal health: heart disease and type 2 diabetes
Layman, D. K., Clifton, P., Gannon, M. C., Krauss, R. M., & Nuttall, F. Q. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1571s · Cited by 142
Association of Sickle Cell Trait With Hemoglobin A1c in African Americans
Lacy, M. E., Wellenius, G. A., Sumner, A. E., Correa, A., Carnethon, M. R., Liem, R. I., Wilson, J. G., Sacks, D. B., Jacobs, D. R., Carson, A. P., et al. (2017) · JAMA · doi:10.1001/jama.2016.21035 · Cited by 141 · cited 1×
“3 percentage points when compared with those without the trait (10,11).”
BackgroundLee, A. K., Lee, C. J., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2017) · Diabetes Care · doi:10.2337/dc17-0819 · Cited by 119 · cited 2×
“and race, other important risk factors found in a community-based epidemiologic cohort of older black and white adults with type 2 diabetes include insulin use, poor or moderate versus good glycemic control, albuminuria, and poor cognitive function (46).”
BackgroundRelationship of A1C to Glucose Concentrations in Children With Type 1 Diabetes
Diabetes Research in Children Network (DirecNet) Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1835 · Cited by 115
Empirically establishing blood glucose targets to achieve HbA1c goals
Wei, N., Zheng, H., & Nathan, D. M. (2014) · Diabetes Care · doi:10.2337/dc13-2173 · Cited by 105
Racial Disparity in A1C Independent of Mean Blood Glucose in Children With Type 1 Diabetes
Kamps, J. L., Hempe, J. M., & Chalew, S. A. (2010) · Diabetes Care · doi:10.2337/dc09-1440 · Cited by 97
Selvin, E. (2016) · Diabetes Care · doi:10.2337/dc16-0042 · Cited by 96 · cited 2×
“ences in how A1C relates to average glucose in children or in different ethnicities is an area for further study (8,14,15).”
BackgroundSurveillance of hypoglycemia-limitations of emergency department and hospital utilization data
Karter, A. J., Moffet, H. H., Liu, J. Y., & Lipska, K. J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1014 · Cited by 73 · cited 1×
“and ambulance use substantially underestimate rates of level 3 hypoglycemia (45), yet find high burden of hypoglycemia in adults over 60 years of age in the community (46).”
BackgroundBuse, J. B., KAUFMAN, F. R., Linder, B. L., Hirst, K., ghormli, L. K. E., Willi, S. M., & for the HEALTHY Study Group (2012) · Diabetes Care · doi:10.2337/dc12-0295 · Cited by 67
Frequent monitoring of A1c during pregnancy as a treatment tool to guide therapy
Jovanovič, L., Savas, H., Mehta, M., Trujillo, A., & Pettitt, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1455 · Cited by 60 · cited 1×
“, pregnant women with type 1 diabetes) may require testing more frequently than every 3 months (4).”
BackgroundKarter, A. J., Lipska, K. J., O’Connor, P. J., Liu, J. Y., Moffet, H. H., Schroeder, E. B., Lawrence, J. M., Nichols, G. A., Newton, K. M., Pathak, R. D., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.009 · Cited by 53
Hypoglycemia in older adults with type 1 diabetes
DuBose, S. N., Weinstock, R. S., Beck, R. W., Peters, A. L., Aleppo, G., Bergenstal, R. M., Rodriguez, H., Largay, J. F., Massaro, E. M., Hirsch, I. B., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0268 · Cited by 36 · cited 1×
“type 1 and type 2 diabetes (48,53), are noted as particularly vulnerable to hypoglycemia because of their reduced ability to recognize hypoglycemic symptoms and effectively communicate their needs.”
BackgroundIslet transplantation for hypoglycemia unawareness/severe hypoglycemia: caveat emptor
Harlan, D. M. (2016) · Diabetes Care · doi:10.2337/dci16-0008 · Cited by 25 · cited 1×
“For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (56,57).”
BackgroundMeasurement of Hemoglobin A1c in Patients With Sickle Cell Trait
Rohlfing, C., Hanson, S., & Little, R. R. (2017) · JAMA · doi:10.1001/jama.2017.4643 · Cited by 20 · cited 1×
“3 percentage points when compared with those without the trait (10,11).”
Background
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Laffel, L. M., Kanapka, L. G., Beck, R. W., Bergamo, K., Clements, M. A., Criego, A., DeSalvo, D. J., Goland, R., Hood, K., Liljenquist, D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6940 · Cited by 443
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Maiorino, M. I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2020) · Diabetes Care · doi:10.2337/dc19-1459 · Cited by 364
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S61-S70
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4250208868
- Cited by
- 655
- References
- 59
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 35 · 2023: 57 · 2022: 85 · 2021: 117 · 2020: 202 · 2019: 112
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, glycemic control, diabetes management, clinical guidelines, quality of care, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.